Risk Factor Management for Metabolic Syndrome
| dc.contributor.advisor | Pórszász, Róbert | |
| dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.contributor.author | Yao-Wei, Tsai | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
| dc.contributor.opponent | Drimba, László | |
| dc.contributor.opponent | Szentmiklósi, József András | |
| dc.contributor.opponentdept | Kenézy Kórház Aneszteziológiai és Intenziv Therápiás Osztály | hu_HU |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.date.accessioned | 2022-08-18T08:25:05Z | |
| dc.date.available | 2022-08-18T08:25:05Z | |
| dc.date.created | 2021-08-12 | |
| dc.description.abstract | Metabolic syndrome is a cluster of physiological and metabolic abnormalities such as central obesity, insulin resistance, hypertension, dyslipidemia, high triglycerides, and low HDL. Patients with metabolic syndromes are thought to have a high chance developing cardiovascular events and type 2 diabetes. Treatment for metabolic syndrome is mostly focus on components of risk factors such as hypertension, dyslipidemia, and obesity rather than metabolic syndrome itself. | hu_HU |
| dc.description.corrector | hbk | |
| dc.description.course | általános orvos | hu_HU |
| dc.description.courselang | angol | hu_HU |
| dc.description.degree | egységes, osztatlan | hu_HU |
| dc.format.extent | 35 | hu_HU |
| dc.identifier.uri | http://hdl.handle.net/2437/336565 | |
| dc.language.iso | en | hu_HU |
| dc.subject | Metabolic Syndrome | hu_HU |
| dc.subject | Central Obesity | hu_HU |
| dc.subject | Insulin Resistance | hu_HU |
| dc.subject | Dyslipidemia | hu_HU |
| dc.subject | Hypertension | hu_HU |
| dc.subject | Treatment of Metabolic Syndrome | hu_HU |
| dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
| dc.title | Risk Factor Management for Metabolic Syndrome | hu_HU |